Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, US Commercial News
California, USA
23+ years of experience
Scrip
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Mandy Jackson 25 Nov 2021
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Scrip
By Mandy Jackson 05 Oct 2021
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
Scrip
By Mandy Jackson 10 Aug 2021
For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.
Scrip
By Mandy Jackson 09 Feb 2021
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
Pink Sheet
By Mandy Jackson 27 Nov 2020
Trump administration wants the HIV drug maker to license HHS patents related to pre-exposure prophylaxis. Lawsuit follows Gilead’s request in August for the USPTO’s PTAB to conduct an inter partes review of the four-year-old patents.
Topic Infectious Diseases
Scrip
By Mandy Jackson 27 Nov 2020
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Topic Coronavirus Financing Innovation
Scrip
By Mandy Jackson 27 Nov 2020
Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.
Scrip
By Mandy Jackson 17 Nov 2020
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Scrip
By Mandy Jackson 09 Oct 2020
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
Scrip
By Mandy Jackson 06 Mar 2020
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
Topic Coronavirus
Scrip
By Mandy Jackson 15 Aug 2019
The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.
In Vivo
By Mandy Jackson 02 Jul 2019
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
Topic BioPharmaceutical
Scrip
By Mandy Jackson 02 Jul 2019
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
Scrip
By Mandy Jackson 02 Jul 2019
Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.
Scrip
22 Jul 2022
Scrip
21 Jul 2022
Scrip
15 Jul 2022
Scrip
14 Jul 2022
Scrip
12 Jul 2022
Scrip
08 Jul 2022
Scrip
05 Jul 2022
Scrip
29 Jun 2022
Scrip
29 Jun 2022
Scrip
27 Jun 2022
Scrip
16 Jun 2022
Pink Sheet
06 Jun 2022
Scrip
03 Jun 2022
Scrip
24 May 2022
Scrip
12 May 2022
